Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA7 | P43166 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | XDH | P47989 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964558 | 0.88 | KDM4E (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL25917115 | 0.88 | CA12 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1706757 | 0.88 | TPMT (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL10130179 | 0.88 | ALDH1A1 (0.45) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14060625 | 0.88 | CA12 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8379866 | 0.87 | CA12 (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2903192 | 0.87 | KDM4E (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL793325 | 0.87 | KDM4E (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1707772 | 0.86 | HTT (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5542753 | 0.84 | KMT2A (0.53) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647315-B9 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| EP-3647315-B1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4142707-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | VIVAVISIONSHANGHAILTD (CN) | 2022-05-10 | — | — | US | disclosed |
| US-7973201-B2 | Process for production of halogen-substituted benzenedimethanol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-05 | — | — | US | disclosed |
| EP-1783108-B1 | METHOD FOR PRODUCING HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | SUMITOMO CHEMICAL CO (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100174122-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7678947-B2 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-2033944-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | Sumitomo Chemical Company, Limited (JP) | 2009-03-11 | — | — | EP | disclosed |
| CN-101356146-A | Process for preparing halogen substituted benzenedimethanol | SUMITOMO CHEMICAL CO (JP) | 2009-01-28 | — | — | CN | disclosed |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1783108-A1 | METHOD FOR PRODUCING HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | CA1 715/4885CA2 801/4885CA12 965/4885 |
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | INPP5D, CXCL12, INPPL1 | CA1 1204/4885CA2 136/4885CA12 1643/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | CA1 715/4885CA2 801/4885CA12 965/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CA1 3006/4885CA2 2574/4885CA12 3883/4885 |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | ADH1A, ADH1C, CYP4A11 | CA1 599/4885CA2 2918/4885CA12 563/4885 |
| US-20100174122-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | HRH4, HAX1, XDH | CA1 613/4885CA2 740/4885CA12 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.